

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
29 June 2006 (29.06.2006)

PCT

(10) International Publication Number
WO 2006/067945 A1

(51) International Patent Classification:

A61K 33/06 (2006.01) A61K 8/891 (2006.01)
A61K 8/26 (2006.01) A61P 17/00 (2006.01)

(21) International Application Number:

PCT/JP2005/022139

(22) International Filing Date:

25 November 2005 (25.11.2005)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2004-371895 22 December 2004 (22.12.2004) JP

(71) Applicants (for all designated States except US):

POLA CHEMICAL INDUSTRIES INC. [JP/JP];
6-48, Yayoi-cho, Suruga-ku, Shizuoka-shi, Shizuoka,
4200914 (JP). **TAISHO PHARMACEUTICAL CO.,**
LTD. [JP/JP]; 24-1, Takada 3-chome, Toshima-ku, Tokyo,
1708633 (JP).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **OHARA, Ya-**
suihiro [JP/JP]; c/o POLA CHEMICAL INDUSTRIES


INC., 27-1, Takashimadai, Kanagawa-ku, Yokohama-shi,
Kanagawa, 2210833 (JP). **SUZUKI, Masashi** [JP/JP];
c/o POLA CHEMICAL INDUSTRIES INC., 27-1,
Takashimadai, Kanagawa-ku, Yokohama-shi, Kanagawa,
2210833 (JP). **TAKANO, Norikazu** [JP/JP]; c/o TAISHO
PHARMACEUTICAL CO., LTD., 24-1, Takada 3-chome,
Toshima-ku, Tokyo, 1708633 (JP). **MITSUYAMA,**
Shunpei [JP/JP]; c/o TAISHO PHARMACEUTICAL
CO., LTD., 24-1, Takada 3-chome, Toshima-ku, Tokyo,
1708633 (JP).

(74) Agents: **KAWAGUCHI, Yoshiyuki** et al.; Acropolis 21
Building 6th floor, 4-10, Higashi Nihonbashi 3-chome,
Chuo-ku, Tokyo, 1030004 (JP).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV,
LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG,

[Continued on next page]

(54) Title: EXTERNAL SKIN AGENT COMPRISING MODIFIED CLAY FOR PREVENTING INFLAMMATION



(57) Abstract: To provide An external skin agent that prevents onset of atopic skin inflammations and is low irritant to skin, which is characterized by including: 1) clay modified by a compound having a quaternary amino group; and 2) a polymer or copolymer that has a side chain including a structure similar to a biological component.

** : P < 0.01 VS. NO TREATMENT GROUP (Dunnett test)

: P < 0.05 VS. WHITE PETROLATUM GROUP (Tukcy test)



SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US,
UZ, VC, VN, YU, ZA, ZM, ZW.

RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT,

Published:

— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.